Business Combination (Tables)

12 Months Ended

Dec. 31, 2014

Lumara Health Inc Member

Summary of the components of the estimated purchase price

The following table summarizes the components of the estimated total purchase price at fair value, subject to adjustment upon finalization of Lumara Health's net working capital, net debt and transaction expenses as of the Lumara Acquisition Date (in thousands):

	Total Acquisition Date Fair Value
Cash consideration	$	600,000
Fair value of 3.2 million shares of AMAG common stock		111,964
Fair value of contingent milestone payments		205,000
Estimated working capital and other adjustments		821
Purchase price paid at closing		917,785
Less:
Due from sellers		(5,119	)
Cash acquired from Lumara Health		(5,219	)
Total purchase price	$	907,447

Summary of estimated fair values of the assets acquired and liabilities assumed related to the business combination

The following table summarizes the preliminary fair values assigned to the assets acquired and the liabilities assumed by us at the Lumara Acquisition Date (in thousands):

Accounts receivable	$	34,918
Inventories		30,300
Prepaid and other current assets		3,322
Deferred income tax assets		94,965
Property and equipment		60
Makena marketed product		797,100
IPR&D		79,100
Restricted cash		1,997
Other long-term assets		3,412
Accounts payable		(3,807	)
Accrued expenses		(41,532	)
Deferred income tax liabilities		(293,649	)
Other long-term liabilities		(4,563	)
Total estimated identifiable net assets		701,623
Goodwill		205,824
Total	$	907,447

Pro forma consolidated financial information

In addition, the pro forma combined net income (loss) in fiscal 2013 does not give effect to the elimination of approximately $392.1 million of non-recurring reorganization gains, net of losses and expenses, realized in connection with Lumara Health's exit from bankruptcy in September 2013 as such amounts are not directly related to the acquisition of Lumara Health (in thousands):

	Year Ended December 31,
	2014			2013
Pro forma combined revenues	$	267,705		$	179,561
Pro forma combined net income (loss)	$	(23,942	)	$	463,522

PlasmaTech Biopharmaceuticals Inc Member

Summary of the components of the estimated purchase price

The following table summarizes the total consideration for the MuGard Rights (in thousands):

	Total Acquisition Date Fair Value
Cash	$	3,434
Acquisition-related contingent consideration		13,700
Total consideration	$	17,134

Summary of estimated fair values of the assets acquired and liabilities assumed related to the business combination

The following table summarizes the fair values of the assets acquired related to the business combination as of the MuGard License Date (in thousands):

Assets Acquired:
MuGard intangible asset	$	16,893
Inventory		241
Net identifiable assets acquired	$	17,134